Beckman Coulter Introduces New Integrated Chemistry and Immunoassay Analyzer
The Californer/10285035

~ Beckman Coulter Diagnostics, a leading company in clinical diagnostics, has announced the launch of their latest innovation, the DxC 500i Clinical Analyzer. This new analyzer combines both clinical chemistry and immunoassay capabilities in one integrated system.

As healthcare systems worldwide are adopting networked laboratory models for improved efficiency and patient access, Beckman Coulter is continuously introducing new solutions to meet the needs of these evolving networks. The DxC 500i Analyzer is designed to cater to the specific requirements of satellite or independent laboratories, as well as core laboratories. By utilizing common reagents and consumables across its scalable portfolio, this analyzer allows for commutable patient results, providing strategic benefits for hospitals and healthcare networks in terms of patient care and inventory management.

Kathleen Orland, Senior Vice President and Business Unit General Manager for Chemistry and Immunoassay at Beckman Coulter Diagnostics, stated that the development of the DxC 500i Analyzer is a testament to the company's commitment to meeting the needs of a wide range of laboratories within healthcare systems. She added that this analyzer offers both clinical chemistry and immunoassay testing in one compact package, with reliable performance, practical simplicity, and trusted clinical quality.

More on The Californer
One of the key features of the DxC 500i Clinical Analyzer is its FlexMode operations which prioritize immunoassay and chemistry testing based on each sample's urgency. The dynamic sample handler also allows for repeats and re-runs without operator intervention while simultaneously loading a new sample rack once the previous one has been offloaded. This optimizes rapid throughput within a small footprint. Additionally, the user-friendly interface provides proactive task indicators, step-by-step instructions, and simplified staff onboarding and training.

In January earlier this year, Beckman Coulter introduced another innovative product - the DxC 500 AU Chemistry Analyzer - which offers automated clinical chemistry testing with guided workflows, over 120 assays, and standardized reagents for use across healthcare networks. The DxC 500i Analyzer incorporates the same technology as the DxC 500 AU, including its Six Sigma performance, within its clinical chemistry capabilities.

The DxC 500i Clinical Analyzer is currently available in countries that accept the CE mark. However, it is still pending submission and clearance by the United States Food and Drug Administration for in vitro diagnostic use in the U.S. It should be noted that not all products are available in all countries, and their availability and regulatory status depend on country registration according to applicable regulations.

To stay updated with Beckman Coulter Diagnostics' latest developments, you can follow and connect with them on LinkedIn, X, and Facebook.
Filed Under: Business

Show All News | Report Violation


Latest on The Californer